Voyager Therapeutics (VYGR) Operating Leases (2019 - 2026)

Voyager Therapeutics (VYGR) has 8 years of Operating Leases data on file, last reported at $27.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 21.3% year-over-year to $27.2 million; the trailing twelve-month figure through Mar 2026 stood at $27.2 million (down 21.3% YoY), and the FY2025 full-year result was $28.7 million, down 21.48% from the prior year.
• Operating Leases retreated to $27.2 million in Q1 2026, from $28.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $42.0 million in Q1 2024 to a low of $17.1 million in Q4 2023.
• A 5-year average of $28.5 million and a median of $28.7 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases sank 47.45% in 2022 and surged 115.13% in 2024, its largest moves.
• Tracing VYGR's Operating Leases over 5 years: stood at $20.3 million in 2022, then retreated by 15.77% to $17.1 million in 2023, then jumped by 113.52% to $36.5 million in 2024, then fell by 21.48% to $28.7 million in 2025, then declined by 5.08% to $27.2 million in 2026.
• Business Quant data shows VYGR's Operating Leases at $27.2 million in Q1 2026, $28.7 million in Q4 2025, and $30.5 million in Q3 2025.